Results 251 to 260 of about 28,272 (264)

Proprotein convertase subtilisin/kexin type 9 related familial hypercholesterolaemia

The British Journal of Diabetes & Vascular Disease, 2012
Gain-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations are an uncommon cause of familial hypercholesterolaemia (FH) with a reported frequency of less than 2% in patients with FH in the United Kingdom. We have found a high prevalence of this genotype in our patients with FH in northwest England.
Sally L Hanton, Charles Van Heyningen
openaire   +1 more source

A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9

DNA and Cell Biology, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the most recently identified member of the proprotein convertase family. Genetic and cell biology studies have suggested a critical role of PCSK9 in regulating low-density lipoprotein receptor (LDLR) protein levels and thus modulating plasma LDL cholesterol. Recent data on the molecular basis for
Robert J, Schmidt, Youyan, Zhang, Yang, Zhao, Yue-Wei, Qian, He, Wang, Aimin, Lin, Maria E, Ehsani, Xiaohong, Yu, Guoming, Wang, Jaipal, Singh, Eric W, Su, Shuyu, Li, Robert J, Konrad, Guoqing, Cao   +13 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9 in human disease

2011
Cardiovascular disease (CVD) is the leading cause of death in the 21st century. Among risk factors, hypercholesterolemia and abdominal obesity are directly linked to premature development of atherosclerosis. Familial hypercholesterolemia, commonly due to low-density lipoprotein receptor (LDLR) deficiency, is known to cause premature atherosclerosis and
openaire   +1 more source

Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.

Clinical and experimental rheumatology, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked with cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the ...
Ivan, Ferraz-Amaro, Raquel, López-Mejías, Begoña, Ubilla, Fernanda, Genre, Beatriz, Tejera-Segura, Antonia M, de Vera-González, Agustín F, González-Rivero, Jose M, Olmos, Jose L, Hernández, Javier, Llorca, Miguel A, González-Gay   +10 more
openaire   +1 more source

Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations

Current Opinion in Lipidology
Purpose of review Monoclonal antibodies (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been established in cardiovascular risk prevention. The purpose of this review is to summarize the effects of PCSK9 inhibitors across different patient populations. Recent findings
Paulina Elena, Stürzebecher, Ulrich, Laufs   +1 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin 9 (PCSK9)

Science-Business eXchange, 2008
openaire   +1 more source

Hemmung der Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

CardioVasc, 2013
Valérie Pavlicek, Daniel Urban, Ulrich Laufs   +2 more
openaire   +1 more source

Regulation of proprotein convertase subtilisin/kexin type 9: Therapeutical perspectives

Atherosclerosis, 2011
openaire   +2 more sources

Proprotein-Convertases Subtilysin/Hexin Type 1-9 (PCSK 1-9)

2021
openaire   +1 more source

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.

The Journal of the Association of Physicians of India, 2019
This review describes the endocrine impact of proprotein convertase subtilisin kexin 9 (PCSK9) biology and PCSK9 inhibition. It discusses the relationship of the pituitary, thyroid, parathyroid, pancreatic, adrenal and gonadal hormones with lipid health.
openaire   +1 more source